Initiation of Prandial Insulin Therapy with AIR Inhaled Insulin or Insulin Lispro in Patients with Type 2 Diabetes: A Randomized Noninferiority Trial

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Diabetes Technology & Therapeutics

• Publication date

  2009-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1089/dia.2009.0037PMID 19772446
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Two-Year Efficacy and Safety of AIR Inhaled Insulin in Patients with Type 1 Diabetes: An Open-Label Randomized Controlled Trial

  2009cited by this paper
• Safety and Efficacy of Inhaled Human Insulin (Exubera) During Discontinuation and Readministration of Therapy in Adults with Type 2 Diabetes: A 3-Year Randomized Controlled Trial

  2009cited by this paper
• Efficacy and Safety of AIR Inhaled Insulin Compared to Insulin Lispro in Patients with Type 1 Diabetes Mellitus in a 6-Month, Randomized, Noninferiority Trial

  2009cited by this paper
• Continuous Glucose Monitoring: An Overview of Its Development

  2009cited by this paper
• CGM—A Technology in Evolution

  2009cited by this paper
• Comparison of Prandial AIR Inhaled Insulin Alone to Intensified Insulin Glargine Alone and to AIR Insulin Plus Intensified Insulin Glargine in Patients with Type 2 Diabetes Previously Treated with Once-Daily Insulin Glargine

  2009cited by this paper
• Primary care physician beliefs about insulin initiation in patients with type 2 diabetes

  2008cited by this paper
• Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.

  2008cited by this paper
• AIR® Inhaled Insulin System: a novel insulin-delivery system for patients with diabetes

  2007cited by this paper
• Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.

  2007cited by this paper
• The specificity and molecular basis of α1-adrenoceptor and CXCR chemokine receptor dimerization

  2007cited by this paper
• Pulmonary Function Changes Related to Acute and Chronic Administration of Inhaled Insulin

  2007cited by this paper
• Understanding Diabetes Medications From the Perspective of Patients With Type 2 Diabetes

  2006cited by this paper
• Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes

  2006cited by this paper
• Standardisation of the measurement of lung volumes

  2005cited by this paper
• Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study.

  2005cited by this paper
• Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem.

  2005cited by this paper
• Standardisation of spirometry

  2005cited by this paper
• Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.

  2005cited by this paper
• General considerations for lung function testing

  2005cited by this paper
• Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial.

  2005cited by this paper
• Inhaled insulin: recent advances in the therapy of Type 1 and 2 diabetes

  2004cited by this paper
• Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial.

  2004cited by this paper
• The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

  2003cited by this paper
• Development and Validation of Radioligand Binding Assays to Measure Total, IgA, IgE, IgG, and IgM Insulin Antibodies in Human Serum

  2003cited by this paper
• Exubera. Inhale therapeutic systems.

  2002cited by this paper
• Nonparametric Hypotheses and Rank Statistics for Unbalanced Factorial Designs

  1997cited by this paper

• Inhaled Insulin: More Compelling than Ever

  2016cites this paper
• Newer devices and improved formulations of inhaled insulin

  2015influential citation
• Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents

  2015cites this paper
• Lipid-based carriers for pulmonary products: preclinical development and case studies in humans.

  2014cites this paper
• The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus

  2012cites this paper
• Managing diabetes with inhaled insulin

  2012influential citation
• Humalog (lispro) for type 2 diabetes

  2012influential citation
• Novel non-invasive methods of insulin delivery

  2012cites this paper
• Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta‐analysis of randomised controlled trials

  2011cites this paper
• Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: a systematic review.

  2011influential citation
• Insulin Analogs and Glycosylated Hemoglobin Target of Less Than 7% in Type 2 Diabetes: A Systematic Review of Randomized Trials

  2011cites this paper
• Multiple HbA1c targets and insulin analogues in type 2 diabetes: a systematic review.

  2011cites this paper
• Bundesärztekammer Kassenärztliche Bundesvereinigung Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften

  2011cites this paper
• A psychometric evaluation of the Diabetes Symptom Checklist-Revised (DSC-R) cognitive distress, fatigue, hyperglycemia, and hypoglycemia subscales in patients with type 1 and type 2 diabetes

  2010cites this paper
• A psychometric evaluation of the Diabetes Symptom Checklist-Revised (DSC-R) cognitive distress, fatigue, hyperglycemia, and hypoglycemia subscales in patients with type 1 and type 2 diabetes

  2010cites this paper
• Safety and Efficacy of AIR Inhaled Insulin Compared with Subcutaneous Insulin in Patients Having Diabetes and Asthma: A 12-Month, Randomized, Noninferiority Trial

  2009cites this paper
• Insulin Delivery via Lungs—Is It Still Possible?

  2009cites this paper